UNSPSC 51411710: Papaverine hydrochloride

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C20H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 23473EC6BQ, chemically known as 6,7,3,4-tetramethoxy-1-benzylisoquinoline hydrochloride but more generally known as papaverine hydrochloride, which bears US NIH Compound Identifier 4680. European Medicines Agency schedules Papaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14763MIG.

UNSPSC 51411710 Papaverine hydrochloride, a Commodity code, designates a specific pharmaceutical injectable used in emergency medical and acute-care settings. State and local governments procure this drug primarily through fire rescue services, hospital systems, and health agencies as part of advanced life support medication inventories. The work being solicited under this code involves supplying regulated pharmaceuticals that meet FDA approval, cGMP certification, Drug Supply Chain Security Act compliance, and strict expiration and shelf-life requirements, with vendors obligated to maintain product quality guarantees, arrange expired-material replacement, and provide Safety Data Sheets and accessibility documentation. Fire rescue services and state health agencies are the primary issuing bodies, with Tampa Fire Rescue (part of the City of Tampa) and the Texas Health and Human Services Commission and Minnesota Department of Administration representing recent activity across municipal, state, and multi-state cooperative procurement channels.

Recent opportunities span three distinct procurement models. The City of Tampa issued IFB 26P00188 on April 24, 2026, with a response deadline of April 8, 2026, seeking four advanced life support medication line items (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in early April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, requiring manufacturer pricing through three authorized wholesalers and performance penalties for reporting delays or improper class-of-trade denials. Activity concentrates in the South (Florida), Southwest (Texas), and Upper Midwest (Minnesota, Oregon), with no indication of solicitations in other regions in the recent-opportunities block.